CINECA IRIS Institutional Research Information System

VIVALDI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.261
AS - Asia 4.996
EU - Europa 3.136
SA - Sud America 964
AF - Africa 415
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.792
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.057
SG - Singapore 1.807
CN - Cina 1.206
IT - Italia 934
BR - Brasile 790
HK - Hong Kong 714
SE - Svezia 529
VN - Vietnam 508
DE - Germania 354
GB - Regno Unito 275
CI - Costa d'Avorio 221
FR - Francia 197
BG - Bulgaria 180
RU - Federazione Russa 159
FI - Finlandia 126
JP - Giappone 120
AT - Austria 119
IN - India 118
CA - Canada 114
TR - Turchia 93
BD - Bangladesh 80
KR - Corea 72
AR - Argentina 69
SN - Senegal 60
NL - Olanda 59
IQ - Iraq 58
PL - Polonia 46
MX - Messico 42
ID - Indonesia 33
ES - Italia 32
PK - Pakistan 32
NG - Nigeria 31
UA - Ucraina 29
EC - Ecuador 28
ZA - Sudafrica 25
MA - Marocco 23
VE - Venezuela 23
UZ - Uzbekistan 22
SA - Arabia Saudita 17
LT - Lituania 16
AU - Australia 14
CO - Colombia 14
MY - Malesia 13
KE - Kenya 12
TN - Tunisia 12
CL - Cile 10
CZ - Repubblica Ceca 10
PE - Perù 10
AE - Emirati Arabi Uniti 9
CH - Svizzera 9
EG - Egitto 9
IR - Iran 9
JO - Giordania 9
PA - Panama 9
PH - Filippine 9
PY - Paraguay 9
RO - Romania 9
IE - Irlanda 8
LB - Libano 8
BE - Belgio 7
UY - Uruguay 7
CR - Costa Rica 6
DZ - Algeria 6
IL - Israele 6
JM - Giamaica 6
NP - Nepal 6
HN - Honduras 5
HU - Ungheria 5
PS - Palestinian Territory 5
SV - El Salvador 5
TW - Taiwan 5
AL - Albania 4
AO - Angola 4
AZ - Azerbaigian 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
TH - Thailandia 4
EE - Estonia 3
KG - Kirghizistan 3
KH - Cambogia 3
LV - Lettonia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BB - Barbados 2
BH - Bahrain 2
BJ - Benin 2
BY - Bielorussia 2
GD - Grenada 2
GE - Georgia 2
GR - Grecia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MD - Moldavia 2
MM - Myanmar 2
Totale 17.763
Salva come PNG Salva come JPEG
Città #
Ashburn 1.086
Singapore 988
Hong Kong 702
Santa Clara 627
San Jose 534
Woodbridge 520
Fairfield 450
Chandler 449
Dallas 449
Houston 360
Ann Arbor 336
Shanghai 298
New York 226
Abidjan 221
Los Angeles 203
Beijing 202
Seattle 184
Wilmington 182
Sofia 179
Boardman 167
Cambridge 165
Ho Chi Minh City 132
Milan 131
Princeton 117
London 116
Florence 109
Munich 108
Council Bluffs 105
Tokyo 104
Lawrence 103
Hefei 99
Lauterbourg 98
Hanoi 96
Vienna 92
Pisa 89
Medford 71
Buffalo 66
Frankfurt am Main 66
Istanbul 61
Dakar 60
Seoul 60
Ottawa 57
São Paulo 51
Serra 50
Redondo Beach 49
San Diego 49
Helsinki 47
Düsseldorf 38
Turku 36
Warsaw 36
Des Moines 35
Rome 33
Nuremberg 32
Fuzhou 31
Baghdad 30
Lancaster 30
Da Nang 29
Lagos 28
Orem 28
Bremen 27
Ogden 27
Dearborn 26
Kent 26
Nanjing 26
Denver 24
Phoenix 23
Cascina 22
Curitiba 20
Haiphong 20
Hyderabad 20
Chennai 19
Tashkent 19
Chicago 18
Colorado Springs 18
Poplar 17
Stockholm 17
Dong Ket 16
Hebei 16
Montreal 16
Quanzhou 16
Rio de Janeiro 16
Boston 15
Mexico City 15
Lappeenranta 14
Norwalk 14
Seacroft 14
Toronto 14
Belo Horizonte 13
Manchester 13
Brooklyn 12
Changsha 12
Guangzhou 12
Lucca 12
Quito 12
Vicopisano 12
Brasília 11
Dhaka 11
Porto Alegre 11
Shenyang 11
Amsterdam 10
Totale 11.787
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 323
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 219
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 199
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 193
In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration 191
Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients 190
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 187
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 182
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 178
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 176
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 173
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 170
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 170
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. 170
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 169
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 168
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 166
Tumor regression grade (TRG) evaluation of 29 borderline/locally advanced pancreatic cancers (LAPCs) after neoadjuvant chemotherapy (NACT) using different pathological scores: a clinical and prognostic correlation 164
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 159
Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma 159
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data 157
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 157
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 156
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 156
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 156
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 155
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 152
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 151
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 150
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 149
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 147
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 145
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) 145
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology 144
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 142
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 142
Neuroendocrine Liver Metastases 138
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 137
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 137
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer 137
Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence. 136
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 136
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 136
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 136
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 136
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 135
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 135
Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection 135
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. 134
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 134
Robotic Versus Open Pancreatoduodenectomy With Vein Resection and Reconstruction: A Propensity Score-Matched Analysis 132
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 132
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 132
Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis 131
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 130
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 129
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 129
Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter. 129
Not only chemotherapy in the second-line treatment of metastatic gastric cancer. 129
Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions 129
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond 128
Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation 128
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 127
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 126
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. 126
Resectable liver metastases from colorectal cancer: where we are now and where do we go from here? 125
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 122
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 122
Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications 119
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 118
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 117
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 117
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 116
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 116
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer 116
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 116
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 116
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 115
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 115
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: Is hepatic arterial infusion chemotherapy the best option? 115
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 115
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer 115
Cholangiocarcinoma: new perspectives for new horizons 115
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 113
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 112
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 111
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 110
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 109
Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres 107
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 107
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 106
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 106
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 105
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 104
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 103
Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study 102
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 102
Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study) 102
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 101
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study 100
Totale 13.859
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.144
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.144
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021114 0 0 0 0 0 0 0 0 0 0 30 84
2021/20221.030 14 20 17 27 171 217 30 35 67 81 90 261
2022/20231.863 186 280 154 93 177 206 15 128 450 7 141 26
2023/20241.209 73 96 144 54 161 171 154 47 37 41 90 141
2024/20254.850 28 199 90 236 443 677 370 197 495 550 616 949
2025/20266.086 500 733 631 684 741 479 935 352 357 615 59 0
Totale 18.164